Stoke Therapeutics (STOK) Equity Ratio (2018 - 2026)

Stoke Therapeutics' Equity Ratio history runs 9 years deep, the most recent figure standing at 0.89 for Q1 2026.

• In Q1 2026, Equity Ratio rose 3.54% year-over-year to 0.89; the TTM figure through Mar 2026 stood at 0.89 (up 3.54% YoY), while the FY2025 annual figure was 0.84, changed 0.12% from the prior year.
• Equity Ratio was 0.89 for Q1 2026 at Stoke Therapeutics, up from 0.84 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2026 to a low of 0.68 in Q1 2024.
• Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.76 in 2022.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio fell 22.84% in 2022, then rose 25.79% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.72 in 2022, then declined by 3.2% to 0.7 in 2023, then increased by 20.69% to 0.84 in 2024, then decreased by 0.12% to 0.84 in 2025, then grew by 5.76% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.84 (Q4 2025), and 0.86 (Q3 2025), per Business Quant data.